1. Introduction {#s0005}
===============

In recent years, enormous reviews and publications have wedged the global researchers establishing the possibility of the utilization of mushrooms. They remain considered to possess many potent health-promoting agents with a variety of bioactivity ([@b0015], [@b0020], [@b0040], [@b0035], [@b0060], [@b0165], [@b0300], [@b0320]; Yanan [@b0345]). They are as dietary supplements for their hypoglycemic activities ([@b0105]). Bioactive compounds are dynamically considered, and their prospective solicitations are sustained by novel proof on health welfares ([@b0170], [@b0080], [@b0085], [@b0090]). It is prominent that the study on basidiomycetes mushroom fungi has facilitated to clarify the massive prospective of these fungi for improving of novel expertise, food, medications, and beauty products as the world of this scientific research anticipated ([@b0125], [@b0110], [@b0140]; [@b0305], [@b0130]). Basidiomycetes mushroom fungi are essential dietary constituents in some cultures, used up in day-to-day food from the ancient times ([@b0340], [@b0145], [@b0150]). Edible mushrooms are found to be a valued nutritional basis for human beings due to their small quantum of calories and also for their health promoting effects (Marina [@b0205]). Conventionally medicinal mushrooms are utilized as antidiabetic nutrition for over a period of several decades in many countries ([@b0270], [@b0275], [@b0280], [@b0395], [@b0295]).

Diabetes Mellitus (DM), metabolic syndrome that has become more and more prevalent and rampant throughout the world. Diabetes incorporates various disorders considered by the raised blood glucose levels (hyperglycemia) ([@b0025]). Clinically, DM is linked with failure of beta cells to secrete adequate pancreatic hormone ([@b0365]). The researched identity of diabetes is chiefly noticed, recorded and marked by certain parameters which deal with the decreased secretion and resistance of insulin in target cell ([@b0350], [@b0225], [@b0315]). In adult-onset diabetes that is noticeable by fating and postprandial sugar level and reduced hormonal secretion are closely connected and diagnosed with type 2 DM ([@b0355], [@b0055], [@b0290]). Several impediments are made because of hyperglycemia, which is an outcome of late and inappropriate healing treatments of diabetes mellitus ([@b0425]). Through over oxidation, free radicals are produced and that take up to oxidative anxiety, cell injury and finally various long-lasting illnesses because of the factors like insalubrious food varieties, the standard of living ecological factors and radiation. Reactive oxygen species (ROS) will be produced with an increased amount of blood glucose level, and this will result in cell membrane impairment and damage of β-cells ([@b0030], [@b0360]).

Research has revealed that mushrooms might assuage the damage of β-cells of the pancreas and increase the synthesis of insulin in STZ-NA diabetic animals compared to normal animals ([@b0065]). Plentiful experiments (both *in vitro* and *in vivo*) have revealed that eatable and therapeutic mushrooms own antioxidant-rich mycochemicals ([@b0370]). Mushrooms could be taken up as a robust approaches of producing the agents for inhibiting oxidation and control of microorganisms ([@b0250], [@b0385], [@b0390]). Extractable metabolites from these mushrooms can be retailed as a pill for ailments hindrance ([@b0135], [@b0420]). Numerous biological activities have been reported from *Pleurotus,* such as antimicrobial, antioxidant, hypoglycemic and so on ([@b0100], [@b0415]).

For a reason, that of apparent efficiency, negligible side effects in medical practice and reasonably economical, natural drugs are extensively approved even after their biologically vigorous composites are mysterious. The current work is an effort to assess the antidiabetic potential of an edible basidiomycetes mushroom fungi, *Pleurotus pulmonarius*. This effort may be a milestone in producing a new medication from uncharted basidiomycetes sp., for the use of the human beings in a better way for the cure of the diabetes mellitus.

2. Materials and methods {#s0010}
========================

2.1. Chemicals and standard drugs {#s0015}
---------------------------------

Streptozotocin and Glibenclamide were obtained from Sigma--Aldrich, USA. All other chemical and solvents were procured from Hi-media Laboratories Pvt., Ltd., India.

2.2. Basidiomycetes mushroom sample preparation {#s0020}
-----------------------------------------------

*Pleurotus pulmonarius*, an edible basidiomycete mushroom fungus, was used in this study. Mycelial agar plugs (8 mm dia) taken from the growing edge of a seven days-old culture of *P. pulmonarius* were transferred aseptically to the sterile Potato Dextrose Broth (PDB). The flasks were then incubated in static condition for 28 days at 28 ± 2 °C for harvesting the mycelial biomass. The mycelia were separated from the media by vacuum filtration through Whatmann No. 1 filter paper. The biomass thus harvested was washed with sterile water, dried by using blotting paper, weighed and preserved for further studies. The dried mycelial biomass was ground to a fine powder by means of a mortar and pestle and was utilized for further extraction of organic compounds. Using soxhlet extraction apparatus with acetone and hot water the mycelial biomass were extracted. After the completion of extraction process, the solvent/water was evaporated by desiccation and used for further studies.

2.3. Animal management {#s0025}
----------------------

Male Swiss albino mice weighing 18 -- 25 g, and both sex of wistar albino rats (150 -- 200 g weight) were used in the present study. The experimental animals were received from Kerala Veterinary and Animal Science University, Mannuthy, Thrissur, Kerala, India. Paddy husk was used as bedding for the animals which were placed for experimental procedure and then assigned to various control and test groups in propylene cages. Experimental rats were retained at 24 ± 2 °C temperature and 30--70% relative humidity with light:day (12:12) cycle. All experimental rats were permitted to freely access the water and feed with pelleted rat chow (M/s. Hindustan Lever Ltd, Mumbai, Maharashtra, India). The institutional animal ethical committee reviewed all the experimental procedures executed in the present study (688/PO/Re/S/02/CPCSEA; Proposal Number: NCP/IAEC/2017--2018/15) and were under the Institutional Ethical Guidelines.

2.4. Acute toxicity study {#s0030}
-------------------------

To execute the acute toxicity studies using experimental animals, the Organization of Economic and Cooperation Development (OECD-423) guidelines were followed. In the present study, the random sampling technique was involved in the case of Swiss albino mice (male). Four hours fasted animals allowed to freely access the water. Initially, Hot Water Extracts (HWE) and Acetone Extracts (AE) of *Pleurotus pulmonarius* at a concentration of 5 mg/kg body weight was orally administered and observed for any mortality. The observation continued for the first 24 hrs and after 72 hrs are over. The Mortality witnessed in any two of the three animals, the administered dose was considered to be lethal. The observation of mortality in an animal out of three animals tested, then the similar dose will be continued to confirm the lethal effect. If there is no mortality, then higher doses (50, 300, 2000 mg/kg) of the extracts were be used for further toxicity study. The general behaviours like sedative, hypnotics, convulsion, ptosis, analgesia, stupar reaction, motor activity, muscle relaxant, pilo erection, change in skin color, lacrimal secretion, and stool consistency were monitored during the study period ([@b0075]).

2.5. Investigational stimulation of diabetes in mice {#s0035}
----------------------------------------------------

Diabetes was experimentally induced through intra-peritoneal injection in twelve hours fasted experimental animals with Streptozotocin (STZ) (55 mg/kg body weight) dissolved in 100 mM citrate buffer (pH 4.5); followed by Nicotinamide (120 mg/kg) after 15 min. After 6 hr of STZ administration, a 10% glucose solution was provided to all the rats to prevent hypoglycemic shock. On completion of 72 h testing and monitoring, rats above 200 mg/dL of blood glucose concentration noticed to be diabetic and this conceptualization could be used for further study.

2.6. Experimental design {#s0040}
------------------------

The following group of studies were carried out, where Group I refers to be as control; Group II and III were considered to be the negative and positive control respectively.Group I:0.1% Carboxy Methyl Cellulose Solution (1 mg/kg)Group II:Streptozotocin (45 mg/kg., i.p) and Nicotinamide (120 mg/kg., i.p)Group III:Glibenclamide (5 mg/kg)Group IV:HWE of *P. pulmonarius* (200 mg/kg)Group V:HWE of *P. pulmonarius* (400 mg/kg)Group VI:AE of *P. pulmonarius* (200 mg/kg)Group VII:AE of *P. pulmonarius* (400 mg/kg)The levels of blood glucose were quantified from the experimental animals over a period of 28 days of drug administration at regular intervals. On 28th day, the animals went on fasting for a night, anesthetized with Pentobarbitone sodium anesthesia (60 mg/kg, i.p). Subsequently, the blood samples were collected in non-heparinized tubes, placed undisturbed for 30 min and processed to obtain serum. The lipid profiles, liver function and kidney function test were tested from the supernatant. All the animals were sacrificed with excess Pentobarbitone sodium. After that the pancreas, liver and kidney were separated out and retained in 10% formalin solution for histopathological studies.

2.7. Preparation of homogenate {#s0045}
------------------------------

Phosphate buffer (200 mM; pH 6.6) was used to homogenate the collected liver from the animals. The obtained homogenate was centrifuged and used for enzymatic and non-enzymatic tests.

2.8. Estimation of serum lipid profile {#s0050}
--------------------------------------

### 2.8.1. Total cholesterol {#s0055}

Total cholesterol (TC) of the samples were estimated calorimetrically. Free cholesterol and free fatty acids were formed by the hydrolyzation of cholesterol esters by cholesterol esterase. The pre-existing ones and the free cholesterol produced in the reaction got oxidized by cholesterol oxidase to cholest-4-en-3-one and hydrogen peroxide. The formed H~2~O~2,~ reacted with 4-aminoantipyrine and phenol in the presence of peroxidase to produce red coloured quinoneimine dye. Ten micro litre of sample was mixed with one ml of test reagent, incubated at 37 °C for 5 min. The cholesterol concentration was proportional to the intensity of the colour produced. The absorbance was measured at 510 nm against a blank. Cholesterol concentration was expressed as mg/dL ([@b0310]).

### 2.8.2. Triglycerols {#s0060}

Serum triacylglycerols (TG) were quantified by the formation of dihydroxyacetone phosphate and hydrogen peroxide from oxidation of glycerol 3 phosphate ([@b0375]). Ten micro litre of serum sample was mixed with one ml of test mixture and incubated at 37 °C. The optical density was measured at 510 nm against a blank and the content of triglycerides was expressed as mg/dl.

### 2.8.3. HDL cholesterol {#s0065}

The Very Low-Density Lipoprotein (VLDL) and Low-Density Lipoprotein (LDL) fractions of plasma samples were precipitated using phosphotungstic acid and then HDL in the supernatant was separated by centrifugation and measured for its cholesterol content. Two hundred micro litre of sample was mixed with 500 μl of precipitation reagent and centrifuged at 4000 rpm for 10 min. The cholesterol extracted in supernatant was estimated as described by [@b0195].

HDL Cholesterol = ΔAsample / ΔAstandard × concentration of standard.

### 2.8.4. LDL & VLDL cholesterol {#s0070}

LDL and VLDL were calculated according to the formula of [@b0115].

VLDL cholesterol = Triglycerides / 5

LDL = TC -- (HDL + VLDL)

The values were expressed as mg/dl

2.9. Determination of blood urea {#s0075}
--------------------------------

The method of [@b0220] was followed to estimate blood urea. Three glass tubes were marked as B, T, and S. In glass tube B and T, 0.02 ml of H~2~O and 0.02 ml of blood was pipetted respectively. Tube S was pipetted with 0.02 ml standard urea solution (0.04%). Hundred microliter of diacetyl monoxime solution and 5 ml of thiosemicarbazide was incorporated into all the glass-tubes. Reagents were vortexed and kept in a hot bath and then cooled. The absorbance was read at 500 nm and the content of urea was expressed as mg/dl.

2.10. Determination of serum creatinine {#s0080}
---------------------------------------

The serum creatinine was estimated by method ([@b0335]). Labeled three test-tubes as B, T and S. into B, pipetted, 2 ml of water, into T, 2 ml serum and 4 ml of water, into S, three ml of H~2~O and one ml of creatinine standard (4 mg/dl). 2 ml of ammonium sulphate and in all tubes, 2 ml of sodium tungstate was added. Three ml of supernatant was removed after centrifugation from each test tube. 1 ml of distilled water and picric acid was added to the test tubes B, T and S. Optical density was read at 520 nm and serum creatinine was calculated as mg/dl.

2.11. Determination of serum insulin {#s0085}
------------------------------------

Serum insulin was assessed following radioimmunoassay technique ([@b0160]). The insulin existing in the test serum competes with the radio-labeled insulin for its antibody when mixed to a tube comprising a stable volume of antibody and a constant volume of the insulin (I^125^-labelled). The quantity of radio-labeled insulin destined to the antibody was in reverse related to the aggregate of insulin in the serum sample. Gamma scintillation counter was used to measure the bound radiolabeled insulin.

2.12. Determination of Malondialdehyde (MDA) {#s0090}
--------------------------------------------

The estimation is carried out by following [@b0230]. Fivefold dilution of serum is made and to this 1 ml of Trichloroacetic acid, 2-thiobarbituric acid and hydrochloric acid in 1:1:1 ratio was added and centrifuged. The optical density of the pink color formed in the supernatant considered to be directly proportional to the concentration of serum MDA was read at 535 nm. The values were indicated as nano moles of MDA/min/mg protein.

2.13. Estimation of lipid hydroperoxides {#s0095}
----------------------------------------

Around 100 µl of homogenized tissue was treated with 900 µl of Fox reagent and incubated for 30 min. The optical density was measured after the colour development at 560 nm using a spectrophotometer. The concentration of lipid hydroperoxides were indicated as nano moles/mg protein ([@b0230]).

2.14. Determination of enzymatic Anti-Oxidants {#s0100}
----------------------------------------------

### 2.14.1. Superoxide dismutase (SOD) {#s0105}

The strength of SOD was quantified by the hindrance of auto catalyzed adrenochrome development in the tissue homogenate at 480 nm following the method of [@b0210]. SOD was indicated as units/mg tissue protein.

### 2.14.2. Catalase (CAT) {#s0110}

The potency of catalase was assessed by the procedure of [@b0010]. One unit of catalase enzyme action was specified as the quantity of enzymes causing the degradation of micro mol H~2~O~2~/mg protein/min at 25 °C.

### 2.14.3. Peroxides (Px) {#s0115}

Peroxidase was estimated by a subsequent modification in optical density at 460 nm by the addition of oxygen to O-dianisidine in the occurrence of enzyme source and hydrogen peroxide. Unit of enzyme activity defined as µmol O-dianisidine/min at 37 °C ([@b0190]).

### 2.14.4. Glutathione peroxidase (GPx) {#s0120}

GPx was measured by the procedure of [@b0255] and expressed as µg of GSH utilized/min/ mg of protein.

### 2.14.5. Glutathione reductase (GSSH) {#s0125}

GSSH was quantified by the procedure of [@b0285]. The activity was expressed by the amount of Nicotinamide adenine dinucleotide phosphate hydrogen consumed in the translation of oxidized glutathione (GSSG) to reduced glutathione (GSH). Glutathione reductase was stated as moles of NADPH oxidized/min/mg at 30˚ C.

2.15. Determination of non-enzymatic antioxidant {#s0130}
------------------------------------------------

### 2.15.1. Reduced glutathione (GSH) {#s0135}

The quantification protocol was centred on the response of GSH with dithionitrobenzoic acid (DTNB) to yield a molecule that is absorbed in 412 nm ([@b0045]). Concisely, 500 µl of supernatant after centrifugation was reserved and mixed with 2 ml of 300 mM disodium hydrogen phosphate solution. To the reaction mixture, 200 µl DTNB was added. The absorbance of the reaction mixture was noted immediately and expressed in micro mol GSH/min/mg protein.

### 2.15.2. Vitamin E {#s0140}

Tissues were homogenized in 0.54 M KCl solution and the mixture containing 1.5 ml of tissue homogenate, 1 ml absolute alcohol and 0.5 ml of 25% ascorbic acid as an antioxidant was incubated. One milliliter of 10 N KOH was added and incubated further in an ice-bath and 4 ml hexane was added to extract and mixed by vortexing for a min. The hexane layer was unglued and the resulting residue was dissolved in 20--50 µl of pure chloroform and spotted on silica gel plates. The alpha tocopherol standard was also spotted, keeping 2 cm distance using benzene : ethyl acetate (2:1) as the running solvent system. Reference plates were flood with 0.001% florescent rhodamine dye dissolved in methanol. From the test silica gel plate, an area corresponding to R~f~ of the alpha tocopherol standard was scraped and eluted. Elute was added with 0.2% bathophenanthroline, followed by FeCl~3~ and 0.001 M *ortho*-phosphoric acid. The optical density was measured at 536 nm against distilled water.$$\text{Conc}.{\mspace{6mu}\text{of\ Vitamin\ E}\mspace{6mu}} = \,\frac{\text{Ab}.{\mspace{6mu}\text{of\ the\ test}\mspace{6mu}} - {\mspace{6mu}\text{Ab}}.{\mspace{6mu}\text{of\ blank}}}{\text{Ab}.{\mspace{6mu}\text{of\ Std}\mspace{6mu}} - {\mspace{6mu}\text{Ab\ of\ blank}}}\,{\text{x}\mspace{6mu}\text{Conc}}.{\mspace{6mu}\text{Std}}$$

The alpha tocopherol concentration in the sample was represented as μg/mg protein ([@b0070]).

### 2.15.3. Vitamin C {#s0145}

Vitamin C was estimated following the procedure of [@b0240]. To 500 µl of sample, 1 ml of 5% TCA was added. The mixture was centrifuged at 4 °C at 14,000 × g for 20 mins. The supernatant (270 µl) was added with 0.08 ml of 85% phosphoric acid, 1.37 ml of 0.5% dipyridyl and 0.028 ml of 1% FeCl~3~. The sample mixture was thoroughly mixed for 60 min for the development of ferrous--dipyridyl chromophore. Samples were centrifuged and optical density was measured at 525 nm.

2.16. Statistical analysis {#s0150}
--------------------------

The experimental data were represented as mean ± SEM. The results were evaluated by using the one-way analysis of variance (One Way ANOVA) using GraphPad version 5. P values \< 0.05 were considered to be significant.

2.17. Histopathological analysis {#s0155}
--------------------------------

The experimental mice were forfeited under light ether anesthesia, by decapitation. The pertinent organ pancreas, liver and kidneys were cut apart out and collected in ten percent formalin solution and straightaway sealed with by the paraffin technique. 5μ thickness slices were taken and stained with hematoxylin and eosin (H and E) for histopathological examination.

3. Results and discussion {#s0160}
=========================

3.1. Oral acute toxicity {#s0165}
------------------------

The results of the acute toxicity study of HWE and AE showed no mortality even after 72 hrs at 2000 mg/kg. The AE showed mile sedation at 2000 mg/kg but however, HWE didn't alter any of the general behavior. No fatality or noxious reactions were found during and after the treatment period with both extracts*.*

3.2. Anti-hyperglycaemic effect {#s0170}
-------------------------------

HWE and AE of *P. pulmonarius* was studied for its hypoglycaemic effect against diabetic rats ([Table 1](#t0005){ref-type="table"}). Diabetes in experimental animals was recognised by the raise in the Blood Glucose Levels (BGL) more than 200 mg/dl later to the administration of STZ.Table 1Effect of different extracts of *Pleurotus pulmonarius* on Blood Sugar Levels in STZ induced diabetic rats.Drug TreatmentMean Blood Sugar Level (mg/dl)Before STZAfter STZ4th Day7th Day14th Day28th DayControl (0.1% CMC)103.66 ± 6.65100.30 ± 7.76104.54 ± 7.3398.71 ± 6.8897.54 ± 6.92103.83 ± 8.72Diabetic Control99.53 ± 5.31223.59 ± 9.35221.62 ± 12.60229.34 ± 9.52220.51 ± 5.83227.58 ± 8.34Reference Control103.16 ± 7.41217.32 ± 8.71210.44 ± 11.96182.05 ± 8.62[\*\*](#tblfn2){ref-type="table-fn"}127.28 ± 8.50[\*\*\*](#tblfn3){ref-type="table-fn"}106.60 ± 8.43[\*\*\*](#tblfn3){ref-type="table-fn"}HWE (200 mg/kg)90.30 ± 4.20218.00 ± 8.13203.27 ± 3.91195.47 ± 3.65163.11 ± 4.06[\*\*](#tblfn2){ref-type="table-fn"}116.54 ± 3.35[\*\*\*](#tblfn3){ref-type="table-fn"}HWE (400 mg/kg)114.60 ± 4.80215.26 ± 6.30210.00 ± 5.24161.09 ± 3.51[\*\*](#tblfn2){ref-type="table-fn"}136.54 ± 6.67[\*\*\*](#tblfn3){ref-type="table-fn"}97.19 ± 5.52[\*\*\*](#tblfn3){ref-type="table-fn"}AE (200 mg/kg)96.53 ± 6.21215.47 ± 7.80219.43 ± 6.24218.34 ± 7.07203.31 ± 6.14197.45 ± 7.75AE (400 mg/kg)88.32 ± 4.44226.24 ± 5.83215.48 ± 4.06206.82 ± 5.11196.27 ± 3.20187.43 ± 5.77[\*](#tblfn1){ref-type="table-fn"}[^2][^3][^4][^5]

BGL in Group III, Group IV and Group V reduced to normal levels after receiving treatment for 28 days. Glibenclamide, used as reference control expressively (P \< 0.001) decreased the BGL from the fourth day onwards. On the 28th day, the blood sugar was found to be (106.60 ± 8.43 mg/dl) but was still a little higher compared with that of Group I (Normal Control). The 200 mg of HWE moderately decreased the blood sugar level (116.54 ± 3.35 mg/dl) from the 4th day onwards and the effect was maintained until the end of the treatment against the reference control (106.60 ± 8.43 mg/dl). The 400 mg/kg of HWE was significant (P \< 0.001), with 97.19 ± 5.52 mg/dl as that of the reference control (106.60 ± 8.43 mg/dl).

Furthermore, the animals in Group VI and Group VII showed higher BGL related with the Group I (p \< 0.05). AE at 200 mg/kg displayed a slight decrease in BGL (197.45 ± 7.75 mg/dl) and 400 mg/kg of AE showed a slightly more decrease in blood sugar (187.43 ± 5.77 mg/dl) level from 14th and 28th day of treatment. Among the two different extracts, HWE showed good hypoglycemic activity against STZ induced diabetes in rats, which displayed substantial (P \< 0.001) decrease in BGL from 7th to 28th day of treatment.

It was apparent, from [Table 2](#t0010){ref-type="table"} that diabetic animals exhibited a drop in insulin concentration. The diabetic animals with commercial drug treatment revealed a extraordinarily increased insulin level related with those in the diabetic control group ([@b0265]). Besides, the insulin content of those animals administered with HWE was significantly (P \< 0.01) lesser in Group I and Group III, but were greater than Group II. The hopeful mode of action whereby HWE facilitated its hypoglycaemic effect possibly will be by increasing insulin sensitivity that was equivalent to be stated in earlier reports ([@b0400], [@b0405], [@b0430]).Table 2Effect of different extracts of *Pleurotus pulmonarius* on insulin level in STZ induced diabetic rats.Drug TreatmentSerum Insulin Level (µU/ml)Control25.66 ± 1.370.1% CMCDiabetic Control6.05. ± 0.25Reference Control17.45 ± 0.95[\*\*\*](#tblfn6){ref-type="table-fn"}Glibenclamide (5 mg/kg)HWE (200 mg/kg)11.24 ± 0.82[\*](#tblfn4){ref-type="table-fn"}HWE (400 mg/kg)16.70 ± 0.96[\*\*](#tblfn5){ref-type="table-fn"}AE (200 mg/kg)8.48 ± 0.14AE (400 mg/kg)14.53 ± 0.48[\*](#tblfn4){ref-type="table-fn"}[^6][^7][^8][^9]

3.3. Lipid profile {#s0175}
------------------

Uncommon fatty acid metabolism in diabetes, may cause dyslipidemia and a sequence of heart diseases and other connected difficulties ([@b0175]). Diabetic dyslipidemia is typically characterized by high difference in serum lipid profiles ([@b0235]). Selected reports also showed that HDL-C played an indispensable role in cholesterol transference and reduces the risk of cardiovascular ailments. Hence, the abnormalities of fatty acid levels in the serum of all experimental groups were investigated.

[Table 3](#t0015){ref-type="table"} shown a noteworthy upsurge in serum lipid levels and expressively decreased in HDL-Cholesterol level as matched to normal control. During the study period, commercial drug, HWE and AE let the decrease in TC, TG, LDL-C and VLDL-C levels (significance of P \< 0.01) of diabetic rats. Whereas HDL-C levels improved related with Group I (p \< 0.001). The outcomes exhibited that commercial drug, HWE and AE could drop the threat of heart diseases by tempering the lipid abnormalities in experimental animals. Notably, HWE (400 mg/kg) showed the lower lipid profile concentrations and the higher HDL-C concentration matched with the AE (400 mg/kg) which exemplifies that the HWE of *P. pulmonarius* showed the more positive effect on lipid profiles than AE.Table 3Effect of different extracts of *Pleurotus pulmonarius* on Lipid Levels in STZ induced diabetic rats.Drug TreatmentLipid Profiles (mg/dl)Total CholesterolTriglycerideHDL - CholesterolLDL - CholesterolVLDL CholesterolControl (0.1% CMC)117.63 ± 8.5265.21 ± 3.6440.27 ± 2.9541.34 ± 2.5516.97 ± 1.08Diabetic Control163.24 ± 8.04121.75 ± 7.6221.54 ± 1.8679.33 ± 6.2434.40 ± 2.76Reference Control124.40 ± 10.63[\*\*](#tblfn8){ref-type="table-fn"}69.27 ± 5.88[\*\*\*](#tblfn9){ref-type="table-fn"}38.65 ± 2.54[\*\*\*](#tblfn9){ref-type="table-fn"}46.30 ± 2.52[\*\*\*](#tblfn9){ref-type="table-fn"}18.39 ± 1.12[\*\*\*](#tblfn9){ref-type="table-fn"}HWE (200 mg/kg)138.10 ± 7.51[\*\*](#tblfn8){ref-type="table-fn"}78.14 ± 5.31[\*\*](#tblfn8){ref-type="table-fn"}28.28 ± 1.11[\*\*](#tblfn8){ref-type="table-fn"}57.44 ± 2.31[\*\*](#tblfn8){ref-type="table-fn"}25.78 ± 1.1[\*\*](#tblfn8){ref-type="table-fn"}HWE (400 mg/kg)125.00 ± 8.44[\*\*](#tblfn8){ref-type="table-fn"}71.59 ± 4.43[\*\*](#tblfn8){ref-type="table-fn"}34.33 ± 1.11[\*\*\*](#tblfn9){ref-type="table-fn"}46.10 ± 1.47[\*\*\*](#tblfn9){ref-type="table-fn"}19.1 ± 1.05[\*\*\*](#tblfn9){ref-type="table-fn"}AE (200 mg/kg)139.46 ± 5.11[\*](#tblfn7){ref-type="table-fn"}82.41 ± 3.41[\*\*](#tblfn8){ref-type="table-fn"}24.39 ± 1.33[\*](#tblfn7){ref-type="table-fn"}64.52 ± 2.31[\*](#tblfn7){ref-type="table-fn"}28.26 ± 1.02[\*](#tblfn7){ref-type="table-fn"}AE (400 mg/kg)130.13 ± 5.71[\*\*](#tblfn8){ref-type="table-fn"}76.63 ± 5.19[\*\*](#tblfn8){ref-type="table-fn"}31.69 ± 1.80[\*\*\*](#tblfn9){ref-type="table-fn"}54.32 ± 1.01[\*\*](#tblfn8){ref-type="table-fn"}22.11 ± 0.99[\*\*\*](#tblfn9){ref-type="table-fn"}[^10][^11][^12][^13]

3.4. Renal functions {#s0180}
--------------------

Diabetic nephropathy (DN) is a severe difficulty of diabetes, categorised by increased size of kidney cells, reduced kidney function and increased urinary albumin evacuation ([@b0215], [@b0005]). DN is one of the main reasons of long-lasting kidney dysfunction and end-stage kidney disease universal, particularly in developed nations and is consequently creating a budding world-wide menace ([@b0440]).

The typical display of the progress of DN in rats is due to the increased level of kidney function test. Similarly, discharge of protein and albumin from urine are the indication of glomerular dysfunction ([@b0410]). Therefore renal function was measured by Serum Creatinine (SC) and Blood Urea Nitrogen (BUN). The experimental results of renal function associated factors were shown in [Table 4](#t0020){ref-type="table"}. SC and BUN in diabetic animals considerably improved related with Group I (P \< 0.001), indicating an injured renal function in these rats. Treatment with glibenclamide / HWE and AE (both lower and higher concentration) considerably (P \< 0.001) declined the elevation of SC and BUN, while BUN concentration in HWE (400 mg/kg) was remarkably lower than the reference control as well.Table 4Effect of different extracts of *Pleurotus pulmonarius* on Kidney functions in STZ induced diabetic rats.Drug TreatmentKidney Function TestBUN (mg/dl)Creatinine (mg/dl)Control (0.1% CMC)17.35 ± 0.960.48 ± 0.02Diabetic Control39.63 ± 2.631.84 ± 0.01Reference Control19.66 ± 1.04[\*\*\*](#tblfn11){ref-type="table-fn"}0.63 ± 0.03[\*\*\*](#tblfn11){ref-type="table-fn"}HWE (200 mg/kg)21.43 ± 1.54[\*\*\*](#tblfn11){ref-type="table-fn"}0.76 ± 0.02[\*\*\*](#tblfn11){ref-type="table-fn"}HWE (400 mg/kg)19.47 ± 1.22[\*\*\*](#tblfn11){ref-type="table-fn"}0.68 ± 0.03[\*\*\*](#tblfn11){ref-type="table-fn"}AE (200 mg/kg)25.11 ± 0.05[\*\*](#tblfn10){ref-type="table-fn"}0.73 ± 0.03[\*\*](#tblfn10){ref-type="table-fn"}AE (400 mg/kg)20.76 ± 0.11[\*\*\*](#tblfn11){ref-type="table-fn"}0.63 ± 0.02[\*\*\*](#tblfn11){ref-type="table-fn"}[^14][^15][^16][^17]

3.5. Malondialdehyde (MDA) and lipid hydroperoxides (LH) {#s0185}
--------------------------------------------------------

Malondialdehyde, the terminal produce of lipid peroxidation conceivably utilized as an evidence of cellular damage. Increased levels of MDA testify severe oxidative impairment (Zhang *et al.,* 2018). As shown in [Table 5](#t0025){ref-type="table"}, MDA and LH status significantly raised in the diabetic rats than Group I (P \< 0.01).Table 5Effect of different extracts of *Pleurotus pulmonarius* on liver MDA and LH in STZ induced diabetic rats.Drug TreatmentMDA (nmoles/min/mg protein)LH (nmoles/min/mg protein)Control (0.1% CMC)0.78 ± 0.030.64 ± 0.04Diabetic Control1.32 ± 0.02[a](#tblfn12){ref-type="table-fn"}1.08 ± 0.02[a](#tblfn12){ref-type="table-fn"}Reference Control0.99 ± 0.01[b](#tblfn13){ref-type="table-fn"}0.87 ± 0.01[b](#tblfn13){ref-type="table-fn"}HWE (200 mg/kg)1.11 ± 0.04[b](#tblfn13){ref-type="table-fn"}0.96 ± 0.01[b](#tblfn13){ref-type="table-fn"}HWE (400 mg/kg)0.91 ± 0.01[b](#tblfn13){ref-type="table-fn"}0.79 ± 0.01[b](#tblfn13){ref-type="table-fn"}AE (200 mg/kg)1.27 ± 0.01[b](#tblfn13){ref-type="table-fn"}0.99 ± 0.03[b](#tblfn13){ref-type="table-fn"}AE (400 mg/kg)1.0 ± 0.03[c](#tblfn14){ref-type="table-fn"}0.93 ± 0.04[c](#tblfn14){ref-type="table-fn"}[^18][^19][^20][^21]

Over 28 days of treatment, conversely, the MDA and LH level was significantly (P \< 0.01) abridged in the diabetic rats. The decreased MDA in rats treated with glibenclamide, HWE and AE perhaps due to the improved actions of free radicals scavenging enzymes ([@b0435]).

3.6. Enzymatic antioxidants {#s0190}
---------------------------

Oxidative stress, by virtue of an unevenness among the hunting of free radicals *in vivo*, possibly will hint to an amplified reactive oxygen species (ROS) or a reduction of free radical scavenging defense ([@b0380]). There are a number of articles resolved that this stress contest a vital role in diabetes and related problems ([@b0260]).

The free radical scavenging enzymes are considered as the primary defence agent against ROS and can defend beside injury ([@b0435]). As revealed in [Table 6](#t0030){ref-type="table"}, anti-oxidative enzyme actions in diabetic animals were suggestively lesser (P \< 0.01) than normal rats. Past publications had shown that STZ possibly will produce ROS, signifying that free radical scavenging treatment may be favourable for considering the oxidative damage of diabetes mellitus ([@b0095]).Table 6Effect of different extracts of *Pleurotus pulmonarius* on liver enzymatic antioxidants in STZ induced diabetic rats.Drug TreatmentCAT (μmoles/min/mg protein)SOD (nmoles/min/mg protein)GSSH (nmoles/min/mg protein)Px (nmoles/mg protein)GPx (nmoles/mg protein)Control (0.1% CMC)42.1 ± 1.85.1 ± 0.0634.8 ± 1.27.6 ± 0.0210.2 ± 0.03Diabetic Control30.6 ± 1.4[a](#tblfn15){ref-type="table-fn"}3.6 ± 0.04[a](#tblfn15){ref-type="table-fn"}21.9 ± 0.8[a](#tblfn15){ref-type="table-fn"}6.2 ± 0.03[a](#tblfn15){ref-type="table-fn"}7.8 ± 0.02[a](#tblfn15){ref-type="table-fn"}Reference Control41.3 ± 2.1[b](#tblfn16){ref-type="table-fn"}4.8 ± 0.05[b](#tblfn16){ref-type="table-fn"}32.6 ± 0.9[b](#tblfn16){ref-type="table-fn"}7.3 ± 0.02[b](#tblfn16){ref-type="table-fn"}9.7 ± 0.06[b](#tblfn16){ref-type="table-fn"}HWE (200 mg/kg)35.1 ± 0.8[b](#tblfn16){ref-type="table-fn"}3.5 ± 0.02[b](#tblfn16){ref-type="table-fn"}24.2 ± 0.4[b](#tblfn16){ref-type="table-fn"}5.4 ± 0.01^c^7.2 ± 0.01[b](#tblfn16){ref-type="table-fn"}HWE (400 mg/kg)38.5 ± 0.8[b](#tblfn16){ref-type="table-fn"}2.8 ± 0.06^c^27.0 ± 0.6[b](#tblfn16){ref-type="table-fn"}5.5 ± 0.04[b](#tblfn16){ref-type="table-fn"}7.5 ± 0.02[b](#tblfn16){ref-type="table-fn"}AE (200 mg/kg)36.1 ± 1.2[b](#tblfn16){ref-type="table-fn"}3.7 ± 0.02[b](#tblfn16){ref-type="table-fn"}26.8 ± 0.9[b](#tblfn16){ref-type="table-fn"}5.5 ± 0.01[b](#tblfn16){ref-type="table-fn"}7.5 ± 0.03[b](#tblfn16){ref-type="table-fn"}AE (400 mg/kg)39.1 ± 1.0[b](#tblfn16){ref-type="table-fn"}3.3 ± 0.04[b](#tblfn16){ref-type="table-fn"}29.7 ± 1.1[b](#tblfn16){ref-type="table-fn"}6.4 ± 0.03[b](#tblfn16){ref-type="table-fn"}8.3 ± 0.06[b](#tblfn16){ref-type="table-fn"}[^22][^23][^24]

After 4 weeks of action with standard drug, there was not any significant rise in the expression of CAT, SOD, GSSH, Px and GPx (*p* \< 0.01). The outcomes recommens that glibenclamide haven't modulated the enzyme activities in diabetic rats, similar to those observed in previous studies ([@b0185]). Contrarily, the treatment of HWE and AE significantly improved the actions of enzymes in diabetic rats matched with diabetic control groups. This demonstrated that HWE and AE could improve the oxidative stress of experimental animals by commendably improvement in actions of antioxidant enzymes.

3.7. Non-enzymatic antioxidant {#s0195}
------------------------------

A substantial reduction in the level of vitamin C, vitamin E, and GSH were detected in diabetic groups when compared with control group. This drop perhaps a significant fact for cell impairment as a result of adverse free radicals generation. HWE and AE tend to fetch these concentrations into close to standard ([Table 7](#t0035){ref-type="table"}). A notable drop in the concentration of GSH was perceived in diabetes-induced rats was raised to a normal level after the treatment. It is confirmed that diabetics consume low concentration of non-enzymatic free radical scavengers and their add-on may help in diabetes cure.Table 7Effect of different extracts of *Pleurotus pulmonarius* on liver non-enzymatic antioxidants in STZ induced diabetic rats.Drug TreatmentGSH (nmoles/min/mg protein)Vitamin C (μg/mg protein)Vitamin E (μg/mg protein)Control (0.1% CMC)12.4 ± 0.94.8 ± 0.037.1 ± 0.02Diabetic Control9.6 ± 0.8[a](#tblfn17){ref-type="table-fn"}3.4 ± 0.02[a](#tblfn17){ref-type="table-fn"}5.8 ± 0.03[a](#tblfn17){ref-type="table-fn"}Reference Control11.8 ± 0.7[b](#tblfn18){ref-type="table-fn"}4.5 ± 0.04[b](#tblfn18){ref-type="table-fn"}6.9 ± 0.02[b](#tblfn18){ref-type="table-fn"}HWE (200 mg/kg)9.2 ± 0.4[b](#tblfn18){ref-type="table-fn"}2.2 ± 0.02[b](#tblfn18){ref-type="table-fn"}5.9 ± 0.03[b](#tblfn18){ref-type="table-fn"}HWE (400 mg/kg)9.8 ± 0.5[b](#tblfn18){ref-type="table-fn"}2.1 ± 0.01[b](#tblfn18){ref-type="table-fn"}5.1 ± 0.02[b](#tblfn18){ref-type="table-fn"}AE (200 mg/kg)9.5 ± 0.7[b](#tblfn18){ref-type="table-fn"}2.6 ± 0.01[c](#tblfn19){ref-type="table-fn"}5.2 ± 0.02[b](#tblfn18){ref-type="table-fn"}AE (400 mg/kg)10.1 ± 0.5[b](#tblfn18){ref-type="table-fn"}3.0 ± 0.01[b](#tblfn18){ref-type="table-fn"}5.6 ± 0.02[b](#tblfn18){ref-type="table-fn"}[^25][^26][^27][^28]

Mostly, these antioxidants are vital to avoid the peroxidation of membrane lipids ([@b0245]). Reduced glutathione, an antioxidant required for cell defense, such as reclamation of ROS, and elimination of poisons ([@b0050]), decrease of tissue reduced glutathione content established evidently states the higher use by the hepatic cells ([@b0120]). In past reports, it was demonstrated that these concentration drops in experimental animals ([@b0325]). It is also detected that the action with glibenclamide, HWE and AE suggestively (P \< 0.01) elevated non-enzymatic antioxidant levels in experimental animals.

3.8. Histopathological analysis {#s0200}
-------------------------------

Histopathological investigations of pancreas, liver and kidney of animals were revealed in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"} and [Fig. 3](#f0015){ref-type="fig"}, respectively. Scientific reviews described that diabetic animals exhibited severe deterioration in the liver ([@b0400], [@b0405]).Fig. 1Histological study of Pancreas of streptozotocin-induced wistar albino rats with different mycelial extracts of *P. pulmonarius.*Fig. 2Histological study of Liver of streptozotocin-induced wistar albino rats with different mycelial extracts of *P. pulmonarius.*Fig. 3Histological study of Kidney of streptozotocin-induced wistar albino rats with different mycelial extracts of *P. pulmonarius*.

In the current work, a microscopic examination of the pancreatic sections of the STZ-induced diabetes rats showed that there were pancreatic acini with diminished islet cells, peripancreatic adipose tissue with swelling and overfilled blood vessels in STZ-induced diabetes rats ([Fig. 1](#f0005){ref-type="fig"}B). Liver tissue was observed with slight modification in structural design, periportal inflammation, broadening of sinusoids, and normal kupfer cell action ([Fig. 2](#f0010){ref-type="fig"}B), while kidney tissues were witnessed with hypercellular glomeruli, thick-walled jammed blood vessels, overfilled proximal convoluted tubules and distal convoluted tubules ([Fig. 3](#f0015){ref-type="fig"}B).

In difference, control animals had an ordered hepatic design with usual pancreatic acini with enlarged ducts, slight stratification, thick-walled overfilled blood vessels and rare islet cells ([Fig. 1](#f0005){ref-type="fig"}A). Normal liver structural design with the usual portal triad and slight central vein jamming were exhibited by liver tissue ([Fig. 2](#f0010){ref-type="fig"}A). Kidney tissue with regular glomeruli with usual proximal convoluted tubules and distal convoluted tubules with normal vascularity were perceived ([Fig. 3](#f0015){ref-type="fig"}A). As shown in [Fig. 1](#f0005){ref-type="fig"}C, 2C and 3C, the pancreas, liver and kidney respectively in animals treated with standard drug almost recuperated to normal.

HWE, AE and glibenclamide therapy enriched the pancreas architecture similar to the control with no alteration. 400 mg of HWE exhibited hyperplasia of pancreatic acini, islet cell pool, overfilled blood vessels and thick-walled ducts ([Fig. 1](#f0005){ref-type="fig"}E); 400 mg of AE exhibited hyperplasia of pancreatic acini with overfilled blood vessels and diminished islet cell pool ([Fig. 1](#f0005){ref-type="fig"}G).

The treatment of HWE (400 mg) significantly marked improvement in the liver histopathology exhibited by liver tissue with minimal congestion of central vein, dilated sinusoids, periportal inflammation, kupfer cell activity, the proliferation of bile ducts and mild ballooning degeneration of the hepatocytes with minimal necrosis. There was no liver cell necrosis witnessed in a higher concentration of hot water extract ([Fig. 2](#f0010){ref-type="fig"}E), Notable changes in liver structural design, central vein jamming and periportal inflammation were observed in 400 mg AE ([Fig. 2](#f0010){ref-type="fig"}G). Histopathological irregularities no longer existed in liver tissue treated with HWE signifying the incredible effect of HWE on enhancing liver defects.

Besides, diabetes is reflected by a series of renal structure irregularity, including membrane thickening ([@b0155]). As revealed in [Fig. 1](#f0005){ref-type="fig"}A, animals in normal control had ample renal architecture. However, the architecture in diabetes animals showed various pathological injuries. 400 mg HWE exhibited hypercellular glomeruli, thinned out cortex, more significant than before perineural adipose tissue, overfilled blood vessels in the interstitium with inflammatory cells composed of lymphoplasmacytes ([Fig. 3](#f0015){ref-type="fig"}E), whereas 400 mg AE displayed kidney with limited jammed hypercellular glomeruli, normal proximal convoluted tubules and distal convoluted tubules with negligible inflammation of the interstitium ([Fig. 3](#f0015){ref-type="fig"}G). 400 mg of HWE had the greatest influence on the defense of the liver beside damages in diabetic animals.

Earlier studies specified that the histological damages in diabetes were mostly validated by the reduction of abnormal amount of lipids and unusual hyperglycemia ([@b0330], [@b0180]), demonstrating that administration of the HWE and AE upturned these morphological changes in the pancreas, liver and kidney of diabetic rats.

4. Conclusion {#s0205}
=============

In conclusion, our study revealed that the HWE and AE revealed antihyperglycaemic, antihyperlipidemic, and defensive effects in diabetic rats by reducing BGL, decreasing lipid profiles, enhancing the status of antioxidants and decreasing injuries in pancreas, liver and kidney. Notably, the HWE exhibited better effects. The outcomes delivered cites for the consumption of the HWE and AE extracted from mycelia of *P. pulmonarius* in relating the inhibition and relief of hyperglycemia. These findings raise the spirits in studying this fungal strain further for its potential biological applications. However, more experimental examination is required to demarcate the mode of action in the defensive effect of these extracts on diabetic animals.
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